Volume Alert - TEVA 57.59 Teva Pharmaceutical Indu
Post# of 116
Posted On: 11/14/2014 2:44:28 PM
Volume Alert - TEVA 57.59 Teva Pharmaceutical Industries Ltd $TEVA Hit a high today of 57.71 Closing the day 10:30 at 57.59 +0.42 +0.73% With a day low of 56.80 and a total volume of 816,311.
TEVA Recent Posts: http://investorshangout.com/Teva-Pharmaceutic...EVA-55623/
TEVA Teva Pharmaceutical Industries Ltd Recent Headline News
Look for Shares of Teva Pharmaceutical Industries to Potentially Rebound after Yesterday's 2.17% Sell Off
Comtex SmarTrend(R) - Thu Nov 13, 4:11PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $57.02 to a high of $58.50. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $57.46 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 57.23 (+0.06)
Teva Pharmaceutical Industries Falls 2.17% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Nov 13, 4:11PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $57.02 to a high of $58.50. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $57.46 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 57.23 (+0.06)
TEVA: Copaxone Patent Expiry Worries Are Overblown
Alpha Gen Capital - at Seeking Alpha - Tue Nov 11, 2:52PM CST
TEVA: 57.23 (+0.06)
Insys Q3 Beats Estimates, Helping Stock Rebound
at Investor's Business Daily - Tue Nov 11, 10:33AM CST
Specialty drugmaker Insys Therapeutics (INSY) beat Wall Street's Q3 estimates Tuesday, sending the stock up around 6% in early trading on the stock market today. Insys' revenue in the quarter totaled $58.3 million, double the year-earlier quarter and...
INSY: 38.52 (-0.19), GWPH: 76.00 (+0.16), TEVA: 57.23 (+0.06), GSK: 45.73 (+0.07)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 111.12 (-1.60), GILD: 101.77 (-2.43), MRK: 58.97 (-0.57), DNDN: 0.11 (-0.02), AZN: 72.72 (-1.81), TEVA: 57.23 (+0.06), ABBV: 63.75 (+0.12), GSK: 45.73 (+0.07), BMY: 57.80 (unch), NVS: 93.89 (-0.49)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 58.97 (-0.57), AZN: 72.72 (-1.81), AMGN: 156.79 (-4.06), TEVA: 57.23 (+0.06), THRX: 13.13 (-0.21), GSK: 45.73 (+0.07), SNY: 46.72 (+0.19), REGN: 393.00 (-9.63), NVS: 93.89 (-0.49)
Global Huntington's Disease Therapeutics Market 2014-2018 - Novel Mechanisms Targeted by Pipeline Candidates
M2 - Tue Nov 11, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbsc46/global) has announced the addition of the "Global Huntington's Disease Therapeutics Market 2014-2018" report to their offering. The Global Huntington's Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018. Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. One key trend emerging in this market is the targeting of novel mechanisms by pipeline molecules. Drugs with novel mechanisms might prove to be better treatment options and might affect the course of the disease through their neuroprotective effects. According to the report, one of the major drivers of the market is the unmet medical needs such as the lack of safe, efficacious, and disease-modifying treatments with regard to the treatment of Huntington's disease. Any drug that can cater to these needs is expected to drive the market during the forecast period. Further, the report states that the poor diagnosis rate is one of the major challenges in this market. This delays the initiation of therapy and affects the quality of life of the patient. Key Vendors - Lundbeck - Valeant Pharmaceuticals International Other Prominent Vendors - Auspex Pharmaceuticals - GlaxoSmithKline - Ipsen - Omeros - Palobiofarma - Pfizer - Prana Biotechnology - Raptor Pharmaceutical - Siena Biotech - SOM Biotech - Teva Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Prevalence of Huntington's Disease - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Clinical-stage Pipeline Candidates - Key Information of Clinical-stage Pipeline Candidates - Discontinued Clinical-stage Pipeline Drugs - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/lbsc46/global
RPTP: 9.82 (-0.46), TEVA: 57.23 (+0.06), ASPX: 24.31 (-0.39), GSK: 45.73 (+0.07), PRAN: 1.69 (-0.03), VRX.TO: 151.31 (+1.16)
Teva Pharmaceutical Industries Earnings Review: 11 Days after Announcement Shares Up 2.2% (TEVA)
Comtex SmarTrend(R) - Mon Nov 10, 11:40AM CST
11 days ago, on October 30th, 2014, Teva Pharmaceutical Industries (NASDAQ:TEVA) reported its earnings. Analysts, on average, expected earnings of $1.24 per share on sales of $5.1 billion. The company actually reported a break-even quarter on sales of $5.1 billion, missing EPS estimates by $1.24 and missing revenue estimates by $37.1 million. Shares of Teva Pharmaceutical Industries have climbed from $56.47 to $57.70, representing a gain of 2.2% since the company reported earnings 11 days ago.
TEVA: 57.23 (+0.06)
Dividend Contenders, Future Champions Or Future Failures: Part 6
Stan Stafford - at Seeking Alpha - Fri Nov 07, 5:13PM CST
PRGO: 153.87 (-1.66), NVO: 44.04 (+0.02), CAH: 80.38 (-0.28), TEVA: 57.23 (+0.06)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 305.50 (-12.48), ALNY: 90.55 (-8.78), ISIS: 48.90 (-1.81), OGXI: 2.13 (-0.02), TEVA: 57.23 (+0.06), RGLS: 17.29 (-0.45), GSK: 45.73 (+0.07), SNY: 46.72 (+0.19)
Uptrend Call Working As Teva Pharmaceutical Industries Stock Rises 10.2% (TEVA)
Comtex SmarTrend(R) - Fri Nov 07, 10:06AM CST
SmarTrend identified an Uptrend for Teva Pharmaceutical Industries (NASDAQ:TEVA) on October 21st, 2014 at $52.51. In approximately 2 weeks, Teva Pharmaceutical Industries has returned 10.17% as of today's recent price of $57.85.
TEVA: 57.23 (+0.06)
Champions Oncology: Marking A Shift Toward Drug Discovery
Ian C. Clift - at Seeking Alpha - Fri Nov 07, 9:14AM CST
Big Pharma is big business, but at a high cost. The most comprehensive industry estimate of productivity for investigational drugs to FDA approval is between 10 to 15% from time of initial clinical investigation. This is due primarily to several...
TEVA: 57.23 (+0.06)
Teva Presents Positive Safety and Efficacy Data for QNASL(R) (Beclomethasone Dipropionate) Nasal Aerosol in Treating Children with Perennial Allergic Rhinitis
Business Wire - Fri Nov 07, 7:00AM CST
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced positive findings from a Phase III clinical study that examined the safety and efficacy of QNASL(R) (beclomethasone dipropionate) Nasal Aerosol 80 g/day in children 4-11 years of age with perennial - or "year round" - allergic rhinitis (PAR). QNASL is a waterless aerosol intranasal corticosteroid spray currently available for the treatment of PAR and seasonal allergic rhinitis (SAR) in patients 12 years of age and older. The data will be presented at the 2014 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Atlanta, Georgia on Saturday, November 8 and Sunday, November 9.
TEVA: 57.23 (+0.06)
Teva Presents Data for Investigational Short-Acting Beta-Agonist Inhaler (Albuterol MDPI) at 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
Business Wire - Fri Nov 07, 7:00AM CST
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that four company-sponsored abstracts evaluating the safety and efficacy of albuterol multi-dose dry-powder inhaler (MDPI), an investigational breath-actuated, dry-powder, short-acting beta-agonist (SABA), will be presented at the 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Atlanta, Georgia on November 6-10, 2014.
TEVA: 57.23 (+0.06)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 202.65 (+0.23), PFE: 30.26 (-0.16), MRK: 58.96 (-0.58), AZN: 72.72 (-1.81), TEVA: 57.23 (+0.06), ITCI: 15.07 (-0.17), ABBV: 63.75 (+0.12), BMY: 57.80 (unch), OMER: 19.11 (-0.46)
Global Irritable Bowel Syndrome Therapeutics Pipeline Review 2014 - 28 Companies & 33 DRug Profiles
M2 - Fri Nov 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/scknzx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - Ono Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - AlbireoPharma - Lexicon Pharmaceuticals, Inc. - Yuhan Corporation - Alba Therapeutics Corporation - Ironwood Pharmaceuticals, Inc. - Rottapharm SpA - Tioga Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Drais Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Protagonist Therapeutics Inc. - Alfa Wassermann S.p.A - RaQualia Pharma Inc. - Furiex Pharmaceuticals, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - X-BODY BioSciences, Inc. - ImmusanT, Inc. - AltheRx Pharmaceuticals, Inc. - GIcare Pharma Inc - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/sc...able_bowel
SGYP: 3.00 (-0.07), FURX: 104.77 (-1.41), SYN: 1.43 (unch), IRWD: 13.04 (-0.45), LXRX: 1.28 (-0.05), AZN: 72.72 (-1.81), TEVA: 57.23 (+0.06)
Global Nerve Gas & Pestiside Poisioning Therapeutics Pipeline Review 2014 - 5 Companies & 6 Drug Profiles
M2 - Fri Nov 07, 5:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/9ccdnh/nerve_gas_and) has announced the addition of the "Nerve Gas & Pestiside Poisioning - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Nerve Gas & Pestiside Poisioning, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nerve Gas & Pestiside Poisioning and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - Teva Pharmaceutical Industries Limited - PharmAthene, Inc. - Protalix BioTherapeutics, Inc. - PlantForm Corporation Drug Profiles - atropine sulfate - PRX-105 - Plasma Derived Butyrylcholinesterase - Second Generation Protexia - Peptides for Nerve Gas and Pestiside Poisioning - Recombinant Butyrylcholinesterase For more information visit http://www.researchandmarkets.com/research/9c...ve_gas_and
BAX: 71.72 (-0.36), PIP: 1.65 (-0.01), TEVA: 57.23 (+0.06)
After Yesterday's Rally of 1.61% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Nov 06, 3:57PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $57.78 to a high of $58.87. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $58.25 on volume of 5.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 57.23 (+0.06)
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries
PR Newswire - Thu Nov 06, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), GlaxoSmithKline PLC (NYSE: GSK), Eli Lilly and Company (NYSE: LLY), and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, November 05, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,484.53, up 0.58% and the NASDAQ Composite closed at 4,620.72, down 0.06%. The S&P 500 finished the session 0.57% higher at 2,023.57. During the trading session, nine out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 778.22, down 0.19%, whereas the index has gained 10.98% in the previous three months. Register for your complimentary reports on these five stocks at:
TEVA: 57.23 (+0.06), LLY: 67.24 (-0.44), ABBV: 63.75 (+0.12), GSK: 45.73 (+0.07), BMY: 57.80 (unch)
TEVA Recent Posts: http://investorshangout.com/Teva-Pharmaceutic...EVA-55623/
TEVA Teva Pharmaceutical Industries Ltd Recent Headline News
Look for Shares of Teva Pharmaceutical Industries to Potentially Rebound after Yesterday's 2.17% Sell Off
Comtex SmarTrend(R) - Thu Nov 13, 4:11PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $57.02 to a high of $58.50. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $57.46 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 57.23 (+0.06)
Teva Pharmaceutical Industries Falls 2.17% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Thu Nov 13, 4:11PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $57.02 to a high of $58.50. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $57.46 on volume of 5.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
TEVA: 57.23 (+0.06)
TEVA: Copaxone Patent Expiry Worries Are Overblown
Alpha Gen Capital - at Seeking Alpha - Tue Nov 11, 2:52PM CST
TEVA: 57.23 (+0.06)
Insys Q3 Beats Estimates, Helping Stock Rebound
at Investor's Business Daily - Tue Nov 11, 10:33AM CST
Specialty drugmaker Insys Therapeutics (INSY) beat Wall Street's Q3 estimates Tuesday, sending the stock up around 6% in early trading on the stock market today. Insys' revenue in the quarter totaled $58.3 million, double the year-earlier quarter and...
INSY: 38.52 (-0.19), GWPH: 76.00 (+0.16), TEVA: 57.23 (+0.06), GSK: 45.73 (+0.07)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 111.12 (-1.60), GILD: 101.77 (-2.43), MRK: 58.97 (-0.57), DNDN: 0.11 (-0.02), AZN: 72.72 (-1.81), TEVA: 57.23 (+0.06), ABBV: 63.75 (+0.12), GSK: 45.73 (+0.07), BMY: 57.80 (unch), NVS: 93.89 (-0.49)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 58.97 (-0.57), AZN: 72.72 (-1.81), AMGN: 156.79 (-4.06), TEVA: 57.23 (+0.06), THRX: 13.13 (-0.21), GSK: 45.73 (+0.07), SNY: 46.72 (+0.19), REGN: 393.00 (-9.63), NVS: 93.89 (-0.49)
Global Huntington's Disease Therapeutics Market 2014-2018 - Novel Mechanisms Targeted by Pipeline Candidates
M2 - Tue Nov 11, 5:15AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbsc46/global) has announced the addition of the "Global Huntington's Disease Therapeutics Market 2014-2018" report to their offering. The Global Huntington's Disease Therapeutics market to grow at a CAGR of 29.46 percent over the period 2013-2018. Huntington's disease is a progressive neurodegenerative disorder that can be inherited from one generation to another as an autosomal dominant trait. It arises due to genetically programmed degeneration of neurons in some parts of the brain such as basal ganglia and cerebral cortex. Basal ganglia plays an important role in coordinating movement while cerebral cortex regulates perception, thought, and memory. Degeneration of neurons leads to progressive cognitive impairment and dementia. One key trend emerging in this market is the targeting of novel mechanisms by pipeline molecules. Drugs with novel mechanisms might prove to be better treatment options and might affect the course of the disease through their neuroprotective effects. According to the report, one of the major drivers of the market is the unmet medical needs such as the lack of safe, efficacious, and disease-modifying treatments with regard to the treatment of Huntington's disease. Any drug that can cater to these needs is expected to drive the market during the forecast period. Further, the report states that the poor diagnosis rate is one of the major challenges in this market. This delays the initiation of therapy and affects the quality of life of the patient. Key Vendors - Lundbeck - Valeant Pharmaceuticals International Other Prominent Vendors - Auspex Pharmaceuticals - GlaxoSmithKline - Ipsen - Omeros - Palobiofarma - Pfizer - Prana Biotechnology - Raptor Pharmaceutical - Siena Biotech - SOM Biotech - Teva Pharmaceutical Industries Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Prevalence of Huntington's Disease - Market Landscape - Market Segmentation by Drug Class - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Clinical-stage Pipeline Candidates - Key Information of Clinical-stage Pipeline Candidates - Discontinued Clinical-stage Pipeline Drugs - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/lbsc46/global
RPTP: 9.82 (-0.46), TEVA: 57.23 (+0.06), ASPX: 24.31 (-0.39), GSK: 45.73 (+0.07), PRAN: 1.69 (-0.03), VRX.TO: 151.31 (+1.16)
Teva Pharmaceutical Industries Earnings Review: 11 Days after Announcement Shares Up 2.2% (TEVA)
Comtex SmarTrend(R) - Mon Nov 10, 11:40AM CST
11 days ago, on October 30th, 2014, Teva Pharmaceutical Industries (NASDAQ:TEVA) reported its earnings. Analysts, on average, expected earnings of $1.24 per share on sales of $5.1 billion. The company actually reported a break-even quarter on sales of $5.1 billion, missing EPS estimates by $1.24 and missing revenue estimates by $37.1 million. Shares of Teva Pharmaceutical Industries have climbed from $56.47 to $57.70, representing a gain of 2.2% since the company reported earnings 11 days ago.
TEVA: 57.23 (+0.06)
Dividend Contenders, Future Champions Or Future Failures: Part 6
Stan Stafford - at Seeking Alpha - Fri Nov 07, 5:13PM CST
PRGO: 153.87 (-1.66), NVO: 44.04 (+0.02), CAH: 80.38 (-0.28), TEVA: 57.23 (+0.06)
Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 305.50 (-12.48), ALNY: 90.55 (-8.78), ISIS: 48.90 (-1.81), OGXI: 2.13 (-0.02), TEVA: 57.23 (+0.06), RGLS: 17.29 (-0.45), GSK: 45.73 (+0.07), SNY: 46.72 (+0.19)
Uptrend Call Working As Teva Pharmaceutical Industries Stock Rises 10.2% (TEVA)
Comtex SmarTrend(R) - Fri Nov 07, 10:06AM CST
SmarTrend identified an Uptrend for Teva Pharmaceutical Industries (NASDAQ:TEVA) on October 21st, 2014 at $52.51. In approximately 2 weeks, Teva Pharmaceutical Industries has returned 10.17% as of today's recent price of $57.85.
TEVA: 57.23 (+0.06)
Champions Oncology: Marking A Shift Toward Drug Discovery
Ian C. Clift - at Seeking Alpha - Fri Nov 07, 9:14AM CST
Big Pharma is big business, but at a high cost. The most comprehensive industry estimate of productivity for investigational drugs to FDA approval is between 10 to 15% from time of initial clinical investigation. This is due primarily to several...
TEVA: 57.23 (+0.06)
Teva Presents Positive Safety and Efficacy Data for QNASL(R) (Beclomethasone Dipropionate) Nasal Aerosol in Treating Children with Perennial Allergic Rhinitis
Business Wire - Fri Nov 07, 7:00AM CST
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced positive findings from a Phase III clinical study that examined the safety and efficacy of QNASL(R) (beclomethasone dipropionate) Nasal Aerosol 80 g/day in children 4-11 years of age with perennial - or "year round" - allergic rhinitis (PAR). QNASL is a waterless aerosol intranasal corticosteroid spray currently available for the treatment of PAR and seasonal allergic rhinitis (SAR) in patients 12 years of age and older. The data will be presented at the 2014 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Atlanta, Georgia on Saturday, November 8 and Sunday, November 9.
TEVA: 57.23 (+0.06)
Teva Presents Data for Investigational Short-Acting Beta-Agonist Inhaler (Albuterol MDPI) at 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
Business Wire - Fri Nov 07, 7:00AM CST
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announced that four company-sponsored abstracts evaluating the safety and efficacy of albuterol multi-dose dry-powder inhaler (MDPI), an investigational breath-actuated, dry-powder, short-acting beta-agonist (SABA), will be presented at the 2014 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) in Atlanta, Georgia on November 6-10, 2014.
TEVA: 57.23 (+0.06)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 202.65 (+0.23), PFE: 30.26 (-0.16), MRK: 58.96 (-0.58), AZN: 72.72 (-1.81), TEVA: 57.23 (+0.06), ITCI: 15.07 (-0.17), ABBV: 63.75 (+0.12), BMY: 57.80 (unch), OMER: 19.11 (-0.46)
Global Irritable Bowel Syndrome Therapeutics Pipeline Review 2014 - 28 Companies & 33 DRug Profiles
M2 - Fri Nov 07, 5:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/scknzx/irritable_bowel) has announced the addition of the "Irritable Bowel Syndrome - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Irritable Bowel Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Irritable Bowel Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Sumitomo Dainippon Pharma Co., Ltd. - Takeda Pharmaceutical Company Limited - Astellas Pharma Inc. - Ono Pharmaceutical Co., Ltd. - SK Chemicals Co., Ltd. - Teva Pharmaceutical Industries Limited - A. Menarini Industrie Farmaceutiche Riunite Srl - AlbireoPharma - Lexicon Pharmaceuticals, Inc. - Yuhan Corporation - Alba Therapeutics Corporation - Ironwood Pharmaceuticals, Inc. - Rottapharm SpA - Tioga Pharmaceuticals, Inc. - Synthetic Biologics, Inc. - Drais Pharmaceuticals, Inc. - Synergy Pharmaceuticals, Inc. - Protagonist Therapeutics Inc. - Alfa Wassermann S.p.A - RaQualia Pharma Inc. - Furiex Pharmaceuticals, Inc. - Hanmi Pharmaceuticals, Co. Ltd. - X-BODY BioSciences, Inc. - ImmusanT, Inc. - AltheRx Pharmaceuticals, Inc. - GIcare Pharma Inc - Dong-A Socio Group For more information visit http://www.researchandmarkets.com/research/sc...able_bowel
SGYP: 3.00 (-0.07), FURX: 104.77 (-1.41), SYN: 1.43 (unch), IRWD: 13.04 (-0.45), LXRX: 1.28 (-0.05), AZN: 72.72 (-1.81), TEVA: 57.23 (+0.06)
Global Nerve Gas & Pestiside Poisioning Therapeutics Pipeline Review 2014 - 5 Companies & 6 Drug Profiles
M2 - Fri Nov 07, 5:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/9ccdnh/nerve_gas_and) has announced the addition of the "Nerve Gas & Pestiside Poisioning - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Nerve Gas & Pestiside Poisioning, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nerve Gas & Pestiside Poisioning and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Baxter International Inc. - Teva Pharmaceutical Industries Limited - PharmAthene, Inc. - Protalix BioTherapeutics, Inc. - PlantForm Corporation Drug Profiles - atropine sulfate - PRX-105 - Plasma Derived Butyrylcholinesterase - Second Generation Protexia - Peptides for Nerve Gas and Pestiside Poisioning - Recombinant Butyrylcholinesterase For more information visit http://www.researchandmarkets.com/research/9c...ve_gas_and
BAX: 71.72 (-0.36), PIP: 1.65 (-0.01), TEVA: 57.23 (+0.06)
After Yesterday's Rally of 1.61% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Nov 06, 3:57PM CST
Teva Pharmaceutical Industries (NASDAQ:TEVA) traded in a range yesterday that spanned from a low of $57.78 to a high of $58.87. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $58.25 on volume of 5.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
TEVA: 57.23 (+0.06)
Technical Notes Covering Pharma Equities - AbbVie, Bristol-Myers Squibb, GlaxoSmithKline, Eli Lilly, and Teva Pharma Industries
PR Newswire - Thu Nov 06, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: AbbVie Inc. (NYSE: ABBV), Bristol-Myers Squibb Company (NYSE: BMY), GlaxoSmithKline PLC (NYSE: GSK), Eli Lilly and Company (NYSE: LLY), and Teva Pharmaceutical Industries Ltd (NYSE: TEVA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Wednesday, November 05, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,484.53, up 0.58% and the NASDAQ Composite closed at 4,620.72, down 0.06%. The S&P 500 finished the session 0.57% higher at 2,023.57. During the trading session, nine out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day at 778.22, down 0.19%, whereas the index has gained 10.98% in the previous three months. Register for your complimentary reports on these five stocks at:
TEVA: 57.23 (+0.06), LLY: 67.24 (-0.44), ABBV: 63.75 (+0.12), GSK: 45.73 (+0.07), BMY: 57.80 (unch)
(0)
(0)Teva Pharmaceutical Industries Limited (TEVA) Stock Research Links
Scroll down for more posts ▼